tolebrutinib
Small moleculeexperimental
Clinical trial activity
14 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
6
Phase 4
0
Earliest trial started Mar 29, 2019 (NCT03889639)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1- Mol. weight
- 455.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650323 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06372145 | Phase 3 | Apr 16, 2024 | Sanofi |
| NCT05282030 | Phase 1 | Mar 23, 2022 | Sanofi |
| NCT05283915 | Phase 1 | Mar 18, 2022 | Sanofi |
| NCT05132569 | Phase 3 | Nov 19, 2021 | Sanofi |
| NCT04742400 | Phase 2 | Apr 15, 2021 | National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) |
| NCT04458051 | Phase 3 | Aug 13, 2020 | Sanofi |
| NCT06106074 | Phase 1 | Aug 10, 2020 | Sanofi |
| NCT04410978 | Phase 3 | Aug 3, 2020 | Sanofi |
| NCT04411641 | Phase 3 | Aug 3, 2020 | Sanofi |
| NCT04410991 | Phase 3 | Aug 3, 2020 | Sanofi |
| NCT06064539 | Phase 1 | May 18, 2020 | Sanofi |
| NCT04171310 | Phase 1 | Dec 31, 2019 | Sanofi |
| NCT03996291 | Phase 2 | Jul 5, 2019 | Sanofi |
| NCT03889639 | Phase 2 | Mar 29, 2019 | Sanofi |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 13 | 13 | 3 | 2019 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1